Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) dropped 5.4% during mid-day trading on Monday after Citigroup lowered their price target on the stock from $11.00 to $10.00. Citigroup currently has a buy rating on the stock. GoodRx traded as low as $6.73 and last traded at $6.82. Approximately 322,501 shares traded hands during trading, a decline of 78% from the average daily volume of 1,463,766 shares. The stock had previously closed at $7.21.
Several other analysts have also weighed in on the stock. Royal Bank of Canada raised shares of GoodRx from a “sector perform” rating to an “outperform” rating and raised their price objective for the stock from $8.00 to $10.00 in a report on Thursday, May 23rd. Morgan Stanley raised their price objective on shares of GoodRx from $7.00 to $9.50 and gave the company an “equal weight” rating in a research note on Monday, June 10th. UBS Group reduced their price target on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research report on Friday. TD Cowen lifted their price target on shares of GoodRx from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, May 16th. Finally, Barclays boosted their price objective on shares of GoodRx from $9.00 to $10.00 and gave the company an “overweight” rating in a research report on Monday, May 20th. One research analyst has rated the stock with a sell rating, four have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $9.36.
Institutional Trading of GoodRx
A number of institutional investors and hedge funds have recently made changes to their positions in the company. GSA Capital Partners LLP acquired a new position in GoodRx during the 1st quarter worth approximately $1,638,000. Rubric Capital Management LP acquired a new position in GoodRx during the 4th quarter worth approximately $39,348,000. Mirae Asset Global Investments Co. Ltd. increased its position in GoodRx by 61.1% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 181,512 shares of the company’s stock worth $1,289,000 after purchasing an additional 68,835 shares in the last quarter. Jupiter Asset Management Ltd. acquired a new position in GoodRx during the 1st quarter worth approximately $707,000. Finally, ClariVest Asset Management LLC acquired a new position in GoodRx during the 1st quarter worth approximately $1,091,000. Institutional investors own 63.77% of the company’s stock.
GoodRx Stock Performance
The stock’s 50-day moving average is $8.27 and its 200-day moving average is $7.39. The firm has a market capitalization of $2.54 billion, a price-to-earnings ratio of -678.00, a PEG ratio of 4.08 and a beta of 1.39. The company has a current ratio of 6.29, a quick ratio of 6.29 and a debt-to-equity ratio of 1.02.
GoodRx (NASDAQ:GDRX – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). GoodRx had a positive return on equity of 3.45% and a negative net margin of 0.86%. The company had revenue of $200.60 million for the quarter, compared to analyst estimates of $200.47 million. During the same quarter in the prior year, the company earned $0.02 earnings per share. GoodRx’s revenue for the quarter was up 5.7% compared to the same quarter last year. On average, analysts predict that GoodRx Holdings, Inc. will post 0.17 EPS for the current fiscal year.
About GoodRx
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.